Nomination Committee appointed for AGM 2020 in Ascelia Pharma AB


Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 6 May 2020 has been appointed

According to the instruction for Nomination Committee in Ascelia Pharma AB (publ) adopted at the annual general meeting held on 14 November 2019, the Nomination Committee shall consist of four members, representing the three largest shareholders per the end of November, together with the chairman of the board of directors. The “three largest shareholders” refer to the ownership grouped registered or in any other way known shareholders as per the end of November.

Based on the above, the Nomination Committee in respect of the AGM that will be held in Malmö on 6 May 2020 has been established to consist of the following persons together representing approximately 40 per cent of the shares and votes in the company:

  • Jørgen Thorball, chairman of the Nomination Committee, appointed by Sunstone Life Science Ventures II K/S;
  • Nils Lorentzen, appointed by CMC SPV of 3 April 2017 AB;
  • Håkan Nelson, appointed by Øresund Healthcare Management A/S; and
  • Peter Benson, chairman of the board of directors.

The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2020 and on the company’s website,

The duties of the Nomination Committee is to prepare and propose the following to the coming annual shareholders’ meeting: election of chairman at the shareholders’ meeting; election of chairman of the board of directors and other members of the board of directors; fees to the board of directors, divided between the chairman and other members, and any fees for committee work; election of auditor and fees to the auditor; and principles for appointment of the Nomination Committee.

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address or alternatively via e-mail Proposals shall be submitted in due time before the Annual General Meeting, but not later than 31 January 2020, to ensure that the proposals can be considered by the Nomination Committee.

For more information, please contact:
Magnus Corfitzen, CEO

Tel. 46 735 179 110

Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 9.30 a.m. CET on 18 December 2019.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit


Information regarding transfer of shares in Ascelia Pharma AB from CMC SPV

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) today announced that it has been informed of that CMC SPV of 3 April 2017 AB (“CMC SPV”) today has divested 687,606 shares in the Company in a private placement to institutional investors and distributed 2,250,000 shares in the Company to its shareholders, including Sunstone and certain members of the board of directors and management of Ascelia Pharma. Followi ...

Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to cancer patients. The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral development plan can be found on its dedicated website.

Ascelia Pharma gets US patent for second generation Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the US Patent Office (USPTO) has issued a new patent covering a second-generation formulation of lead drug candidate Mangoral, currently in the pivotal Phase 3 study SPARKLE. The new patent further improves the unique value proposition of the Mangoral franchise and provides patent protection until year 2040 in the US.